Stanford Cancer Institute member Ami Bhatt, MD, PhD, will be recognized with the William Dameshek Prize for her work in pioneering the development and application of genomic approaches to studying the microbiome—work that has improved outcomes for many human diseases.

In addition, Stanford is proud to have 36 scientists presenting oral abstracts, educational sessions, and workshops at the 2024 American Society of Hematology Annual Meeting, in addition to many poster presentations, which can be found at this link.

2024 Stanford presentations

Ranjana Advani, MD
When Should We Use It? The Role of Brentuximab Vedotin in 2024

Ash Alizadeh, MD, PhD
Circulating Tumor DNA (ctDNA) as an Early Outcome Predictor in Patients (pts) With Second-Line (2L) Large B-Cell Lymphoma (LBCL) After Lisocabtagene Maraleucel (liso-cell) Versus Standard of Care (SOC) Treatment (tx) From the Phase 3, Randomized Transform Study

Circulating Tumor DNA: All You Need is Blood

Jan Boegeholz, MD
Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT Throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Quenton Bubb, MPhil
Development of Multivalent Cell Therapies for Treatment of Hematologic Malignancies

Gerald Crabtree, MD
Heterobifunctional Molecules Targeting Epigenetic Mechanisms

Agnieszka Czechowicz, MD, PhD
Reduced-Toxicity Hematopoietic Stem Cell Therapies for Fanconi Anemia

Kara Davis, DO
Tumor Intrinsic Factors Predicting Antigen Loss

Elizabeth Egan, MD, PhD
Plasmodium Falciparum Influences Erythropoiesis

Bita Fakhri, MD, MPH
Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know

Charles Gawad, MD
Novel Single-Cell Genomics Technologies to Reconstruct Phylogenetics of Human Blood Cells

Jordan Goldstein, MD, MSc
Baseline Prognostic Factors Do Not Predict End of Treatment ctDNA MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL

Zinaida Good, PhD
Heterogeneity of CD19 CAR T Cells

Jason Gotlib, MD, MS
Meet the Blood Editors

Mark Hamilton, MD
Damage to Engineered T Cell Genomes

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Angel Kongsomboonvech, PhD, MHS
Cross-Linking of Erythrocyte CD44 Promotes Plasmodium Falciparum Invasion

Anne Marjin Kramer, MD, PhD
CD22-Directed CAR T Cell Single Cell Multiomic Features Associated With Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS)

Dasom Lee, MD
Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Early Outcomes of a Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Michaela Liedtke, MD
Assessment of Outcomes of Allogeneic Stem Cell Transplantation by Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients With B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trials

Monoclonal Gammopathies: When the Clone is More Than a Positive Laboratory Finding

MGUS Where Do We Stand Today?

Sofia Luna
Engineering Hematopoietic Stem Cells to Generate Therapeutic Antibody Secreting B Cells

Ravi Majeti, MD, PhD
Gene Editing to Model Clonal Hematopoiesis

Gabriel Mannis, MD
IO-202, a Novel Anti-LILRB4 Antibody, With Azacitidine for Hypomethylating Agent-Native Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Kelvin C. Mo, BA
CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes After CAR T Cell Therapy for LBCL

Lori Muffly, MD
Setting Up a Health Services and Outcomes Research Program

Ann Mullally, MD
MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Mutation-Specific Differences in the Relationship Between Obesity and Clonal Hematopoiesis, With a Focus on JAK2V617F and MPN Prevention

Cedric Rossi, MD, PhD
Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified by Comprehensive Genomic Profiling

Kathleen Sakamoto, MD, PhD
Targeting Oxidative Phosphorylation for Pediatric Blood Cancer - From the Lab to the Clinic

Joseph Schroers-Martin, MD
Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

William Shomali, MD
Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis

Melody Smith, MD, MS
Safe and Effective Combination of Donor-Derived, Allogenic CD19/CD22-CAR T Cells With Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Takeshi Sugio, MD, PhD
Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas

Leah Swartzrock
Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation

Kekoa Taparra, MD, PhD
Combatting Structural Racism for Native Hawaiian and Other Pacific Islanders in Health Data

Meghan Thompson, MD
Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients With Chronic Lymphocytic Leukemia (CLL)

Michaela Liedtke, MD

Assessment of Outcomes of Allogenic Stem Cell Transplantation by Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients With B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Ellen Zhang, MD
Long-Term Safety and Effectiveness of Pomalidomide for Bleeding in Hereditary Hemorrhagic Telangiectasia

James Zou, PhD
The Potential and Pitfalls of Generative AI in Basic and Clinical Research

November 2024
Katie Shumake